Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Accuracy of 99mTc-EC-DG SPECT/CT vs 18F-FDG PET/CT in Lung Cancer
NCT01394679Phase 3Not yet recruiting
- Sponsor
- CellPoint
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of technetium-99m ethylenedicysteine-deoxyglucose in lung cancer, sponsored by CellPoint. Primary endpoints: Sensitivity of 99mTc-EC-DG SPECT/CT and Specificity of 99mTc-EC-DG SPECT/CT. Planned start May 2025; status: not yet recruiting.
02
Drugs
technetium-99m ethylenedicysteine-deoxyglucose
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT01394679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394679.